Market Overview

UPDATE: Maxim Group Cuts PT to $24 on ARIAD Pharmaceuticals; Label Warning Reduces Forecast

Related ARIA
Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98
Ariad's Recent Run Has Stock At Highest Levels Since October 2013
Biotech: What's Next For M&A? (Seeking Alpha)

Maxim Group reiterated its Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and a $24 price target.

Maxim Group said, "Unexpectedly, Iclusig's label contains a boxed warning on arterial thrombosis and hepatotoxicity. … The information suggests (1) Iclusig may have an disadvantage in competing against other CML drugs and (2) if physicians reduce dose to 15mg/day because of adverse events, Iclusig may generate smaller sales… We are reducing our peak penetration assumption to 22% from 30% to reflect potential hurdles for doctors to prescribe Iclusig. However, lower penetration is partially offset by higher-thanexpected selling price."

ARIAD Pharmaceuticals closed at $18.93 on Friday.

Latest Ratings for ARIA

Sep 2016Leerink SwannInitiates Coverage onOutperform
Jul 2016BarclaysMaintainsUnderweight
May 2016Cowen & Co.UpgradesMarket PerformOutperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Maxim GroupAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!